Saijo Nagahiro
Medical Oncology Division, Kinki University School of Medicine.
Nihon Rinsho. 2010 Jun;68(6):1007-13.
Antiangiogenesis therapy with bevacizumab demonstrated better response rate, progression free survival and overall survival in various kind of tumors including colon, breast, lung and renal cancer. It mainly potentiates antitumor activity of cytotoxic drugs. Problems remain in high cost of antibody and adverse events such as hypertension and bleeding. Small molecules of VEGF-TKI could not show survival benefit by many randomized controlled trials except for renal and hepatic cancer.
使用贝伐单抗进行的抗血管生成治疗在包括结肠癌、乳腺癌、肺癌和肾癌在内的各种肿瘤中显示出更高的缓解率、无进展生存期和总生存期。它主要增强细胞毒性药物的抗肿瘤活性。抗体成本高以及高血压和出血等不良事件等问题仍然存在。除肾癌和肝癌外，许多随机对照试验表明小分子VEGF-TKI未显示出生存获益。
